Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12371

1.

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.

Spathas N, Economopoulou P, Cheila M, Kotsantis I, Fanouriakis A, Kassara D, Psyrri A.

Front Oncol. 2018 Sep 26;8:409. doi: 10.3389/fonc.2018.00409. eCollection 2018.

2.

[Relationship between Immune Differentiation Antigen and Minimal Residual Disease in Childhood B-ALL].

Wang YF, Zhang G, Jiang YM, Gao J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Oct;26(5):1301-1308. doi: 10.7534/j.issn.1009-2137.2018.05.008. Chinese.

PMID:
30295242
3.

Malakoplakia as a cause of severe hypercalcemia through ectopic 25-hydroxyvitamin D3 1-alpha-hydroxylase expression: A case report.

Chemouny JM, Sannier A, Hanouna G, Champion L, Vrtovsnik F, Daugas E.

Medicine (Baltimore). 2018 Oct;97(40):e12090. doi: 10.1097/MD.0000000000012090.

4.

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

Peltola KJ, Bono P, Jones RH, Vjaters E, Nykänen P, Vuorela A, Oksala R, Pohjanjousi P, Mustonen MVJ, Fizazi K, Massard C.

Eur Urol Focus. 2018 Sep 4. pii: S2405-4569(18)30241-4. doi: 10.1016/j.euf.2018.08.022. [Epub ahead of print]

5.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
6.

Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids.

Abutaleb ARA, McNally EM, Khan SS, Anderson AS, Carr JC, Wilcox JE.

JAMA Cardiol. 2018 Oct 1;3(10):1006-1010. doi: 10.1001/jamacardio.2018.2695.

PMID:
30167630
7.

Alzheimer's Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database.

Lehrer S, Rheinstein PH.

J Alzheimers Dis Rep. 2018;2(1):111-115. doi: 10.3233/ADR-170033. Epub 2018 Jun 29.

8.

Sirolimus-induced severe small bowel angioedema: A case report.

Yang H, Wang W, Hu X, Zhang X, Liu L.

Medicine (Baltimore). 2018 Aug;97(34):e12029. doi: 10.1097/MD.0000000000012029.

9.

Bilateral thalamic and mesencephalic infarctions with hypopituitarism as long-term complications postradiotherapy: A case report.

Hui L, Shijun H, Tao L, Guoqiang W, Shixiong H.

Medicine (Baltimore). 2018 Aug;97(34):e11917. doi: 10.1097/MD.0000000000011917.

10.

Early Sirolimus-Based Immunosuppression is Safe for Lung Transplantation Patients: Retrospective, Single Arm, Exploratory Study.

Wojarski J, Żegleń S, Ochman M, Karolak W.

Ann Transplant. 2018 Aug 23;23:598-607. doi: 10.12659/AOT.908471.

11.

The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.

Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G.

Curr Opin HIV AIDS. 2018 Nov;13(6):512-521. doi: 10.1097/COH.0000000000000502.

PMID:
30124473
12.

The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.

Kerr D 2nd, Sokol L.

Expert Opin Investig Drugs. 2018 Sep;27(9):733-739. doi: 10.1080/13543784.2018.1512970. Epub 2018 Aug 27. Review.

PMID:
30118336
13.

Rapamycin for refractory discoid lupus erythematosus.

Herold M, Richmond NA, Montuno MA, Wesson SK, Motaparthi K.

Dermatol Ther. 2018 Sep;31(5):e12631. doi: 10.1111/dth.12631. Epub 2018 Aug 14.

PMID:
30109759
14.

Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.

Zhao LN, Liang Y, Fang XJ, Liu XM, Jiang QL, Wang SS, She SF, Cao M.

Clin Neurol Neurosurg. 2018 Oct;173:70-76. doi: 10.1016/j.clineuro.2018.07.023. Epub 2018 Jul 30.

PMID:
30092406
15.

Drugs for inflammatory bowel disease.

[No authors listed]

Med Lett Drugs Ther. 2018 Jul 2;60(1550):107-114. No abstract available.

PMID:
30036352
16.

Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.

[No authors listed]

Med Lett Drugs Ther. 2018 Jul 16;60(1551):e122-e123. No abstract available.

PMID:
30036350
17.

Cyclophosphamide-induced Atrial Fibrillation With Rapid Ventricular Rate.

Ejaz K, Raza MA, Maroof S, Haider MW.

Cureus. 2018 May 16;10(5):e2633. doi: 10.7759/cureus.2633.

18.

The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.

Lin Z, Chen X, Li Z, Zhou Y, Fang Z, Luo Y, Zhao J, Xu B.

Ann Hematol. 2018 Nov;97(11):2137-2144. doi: 10.1007/s00277-018-3435-1. Epub 2018 Jul 19. Review.

PMID:
30027435
19.

Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.

Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN, Lo Sicco K.

J Drugs Dermatol. 2018 Jul 1;17(7):807-809.

PMID:
30005106
20.

Management of adverse events related to checkpoint inhibition therapy.

Rudzki JD.

Memo. 2018;11(2):132-137. doi: 10.1007/s12254-018-0416-y. Epub 2018 Jun 12. Review.

Supplemental Content

Loading ...
Support Center